ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

RGNX REGENXBIO Inc

14,50
0,11 (0,76%)
Após o horário de negociação
Última atualização: 19:41:12
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
REGENXBIO Inc RGNX NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
0,11 0,76% 14,50 19:41:12
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
14,76 14,16 14,77 14,33 14,39
mais cotações »

Notícias Recentes

Data Hora Fonte Título
25/07/202408:05PRNUSREGENXBIO to Host Conference Call on August 1 to Discuss..
24/06/202408:05PRNUSREGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to..
18/06/202408:05PRNUSREGENXBIO Announces Successful Pre-BLA Meeting with FDA to..
12/06/202408:05PRNUSREGENXBIO Announces Leadership Transition
05/06/202408:05PRNUSREGENXBIO to Participate in the Goldman Sachs 45th Annual..
10/05/202408:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
08/05/202417:05PRNUSREGENXBIO Reports First Quarter 2024 Financial Results and..
01/05/202408:05PRNUSREGENXBIO to Host Conference Call on May 8 to Discuss First..
24/04/202408:05PRNUSREGENXBIO to Participate in Chardan's 8th Annual Genetic..
28/03/202408:05PRNUSREGENXBIO Announces Lancet Publication of Phase I/IIa Study..
27/03/202417:05PRNUSREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD..
11/03/202408:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
07/03/202401:20PRNUSREGENXBIO Announces Pricing of Upsized Public Offering of..
06/03/202418:10PRNUSREGENXBIO Announces Proposed Public Offering of Common Stock
05/03/202409:05PRNUSREGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM..
29/02/202418:57PRNUSREGENXBIO to Host Webcast Event to Discuss New Interim..
27/02/202418:05PRNUSREGENXBIO Reports Fourth Quarter and Full Year 2023..
21/02/202409:05PRNUSREGENXBIO to Host Conference Call on February 27 to Discuss..
07/02/202413:40PRNUSREGENXBIO Announces Pivotal Trial of RGX-121 for the..
07/02/202409:05PRNUSREGENXBIO Announces Completion of Enrollment in Cohort 2 and..
31/01/202409:05PRNUSREGENXBIO Announces Presentations at the 20th Annual..
16/01/202416:47PRNUSREGENXBIO Announces Positive Interim Data from Phase II..
10/01/202409:05PRNUSREGENXBIO Announces Presentation at the Hawaiian Eye and..
08/01/202409:05PRNUSU.S. District Court Issues Decision on REGENXBIO and..
29/11/202309:05PRNUSREGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE®..
08/11/202318:05PRNUSREGENXBIO Announces Updated Strategic Plans and Third..
07/11/202309:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
03/11/202319:53PRNUSREGENXBIO Presents Positive One Year Data from Phase II..
01/11/202308:05PRNUSREGENXBIO to Host Conference Call on November 8 to Discuss..
30/10/202308:05PRNUSREGENXBIO Announces Presentations at the American Academy of..
05/10/202308:05PRNUSREGENXBIO to Participate in the Jefferies CNS/Neuro Summit
03/10/202317:05PRNUSREGENXBIO Presents Interim Clinical Data from Phase I/II..
26/09/202308:05PRNUSREGENXBIO Announces Presentations at the 28th Annual..
05/09/202308:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
30/08/202308:05PRNUSInitial Clinical Data of First Pediatric CLN2 Patient Dosed..
23/08/202317:05PRNUSREGENXBIO Announces Presentations at the Society for the..
02/08/202317:05PRNUSREGENXBIO Reports Second Quarter 2023 Financial Results and..
01/08/202317:05PRNUSREGENXBIO Announces Participation at the 2023 Wedbush..